Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.

Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, Watkins A, Bilodeau M, Hoffman J, Sanderson P, Hartman G, Mahan E, Prueksaritanont T, Jiang G, She QB, Rosen N, Sepp-Lorenzino L, Defeo-Jones D, Huber HE.

Cancer Biol Ther. 2010 Apr 1;9(7):493-503. Epub 2010 Apr 1.

2.

Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.

Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, Papadopoulos N.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2598-603. doi: 10.1073/pnas.0914018107. Epub 2010 Jan 20. Erratum in: Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6551.

3.

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.

Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.

4.

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F.

Cancer Res. 2009 May 15;69(10):4286-93. doi: 10.1158/0008-5472.CAN-08-4765. Epub 2009 Apr 28.

5.

Tumours with PI3K activation are resistant to dietary restriction.

Kalaany NY, Sabatini DM.

Nature. 2009 Apr 9;458(7239):725-31. doi: 10.1038/nature07782. Epub 2009 Mar 11.

6.

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM.

PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.

7.

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS.

J Biol Chem. 2009 Mar 20;284(12):8023-32. doi: 10.1074/jbc.M900301200. Epub 2009 Jan 15.

8.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK.

Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.

9.

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA Jr, Smith Y, Warmus JS, Tecle H.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4. doi: 10.1016/j.bmcl.2008.10.054. Epub 2008 Oct 15.

PMID:
18952427
10.

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP.

J Clin Invest. 2008 Sep;118(9):3065-74. doi: 10.1172/JCI34739.

11.

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N.

PLoS One. 2008 Aug 26;3(8):e3065. doi: 10.1371/journal.pone.0003065.

12.

Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila.

Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B.

EMBO J. 2008 Sep 17;27(18):2432-43. doi: 10.1038/emboj.2008.163. Epub 2008 Aug 14.

13.

High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.

Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C.

Am J Clin Pathol. 2008 Aug;130(2):247-53. doi: 10.1309/LWDY1AXHXUULNVHQ.

PMID:
18628094
14.

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S.

Neoplasia. 2008 Jun;10(6):534-41.

15.

Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs.

Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, Smith B, Polakiewicz RD, Pelletier J, Ferraiuolo MA, Sonenberg N.

RNA. 2008 Jul;14(7):1318-27. doi: 10.1261/rna.950608. Epub 2008 May 30.

16.

The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases).

Buxade M, Parra-Palau JL, Proud CG.

Front Biosci. 2008 May 1;13:5359-73. Review.

PMID:
18508592
17.

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.

Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M.

J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16. doi: 10.1210/jc.2008-0273. Epub 2008 May 20.

PMID:
18492751
18.

Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.

Bilodeau MT, Balitza AE, Hoffman JM, Manley PJ, Barnett SF, Defeo-Jones D, Haskell K, Jones RE, Leander K, Robinson RG, Smith AM, Huber HE, Hartman GD.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3178-82. doi: 10.1016/j.bmcl.2008.04.074. Epub 2008 May 1.

PMID:
18479914
19.

The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1.

Michlewski G, Sanford JR, Cáceres JF.

Mol Cell. 2008 Apr 25;30(2):179-89. doi: 10.1016/j.molcel.2008.03.013.

20.

Targeting the eukaryotic translation initiation factor 4E for cancer therapy.

Graff JR, Konicek BW, Carter JH, Marcusson EG.

Cancer Res. 2008 Feb 1;68(3):631-4. doi: 10.1158/0008-5472.CAN-07-5635. Review.

Supplemental Content

Support Center